All News
FDA Layoffs in Staff Overseeing Food Safety, Medical Devices, and Tobacco Products
(MedPage Today) -- The Trump administration's effort to slash the size of the federal workforce reached the FDA this weekend, as recently hired employees who review the safety of food ingredients, me
Read MoreFood head at FDA quits citing Trump administration’s mass staff cuts
Jim Jones, who joined Food and Drug Administration in 2023, says layoffs would make it ‘fruitless’ to continue in roleThe head of the food division at the US Food and Drug Administration has quit
Read MoreSTAT+: FDA’s head of device safety among employees terminated in ‘challenging’ weekend
The cuts hit the FDA's medical device center particularly hard, including reviewers and experts on AI-enabled medical technology.
Read More‘Triangle of death’: will Italy finally tackle mafia’s toxic waste dumping?
Cancer rates have soared in Casalnuovo di Napoli, Italy, where burying or burning of waste has poisoned water and landSoon after her son, Antonio, was born, Marzia Caccioppoli moved to Casalnuovo di N
Read MoreAbridge raises $250 million highlighting ‘billable notes’
In this edition of STAT Health Tech: HHS cuts impacting AI regulation at FDA, ambient scribe company Abridge's fundraise, and more.
Read MoreBiogen partners with Stoke Therapeutics to sell severe epilepsy drug
And other biotech stories from the past weekend.
Read MoreTrump Cuts Target CDC Training; Bird Flu Admissions Rise; Ozempic Theft Spree
(MedPage Today) -- Note that some links may require registration or subscription. MedPage Today is collecting stories of HHS staffers across all agencies affected by Trump administration cuts.
Read MoreSTAT+: Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an early sign of promise
Read MoreSTAT+: Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.
Read More